GSK Plc ADR (GSK) concluded trading on Wednesday at a closing price of $35.06, with 6.06 million shares of worth about $212.35 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.37% during that period and on January 29, 2025 the price saw a loss of about -0.11%. Currently the company’s common shares owned by public are about 2.04B shares, out of which, 2.04B shares are available for trading.
Stock saw a price change of 4.88% in past 5 days and over the past one month there was a price change of 2.75%. Year-to-date (YTD), GSK shares are showing a performance of 3.67% which decreased to -10.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $31.72 but also hit the highest price of $45.92 during that period. The average intraday trading volume for GSK Plc ADR shares is 5.42 million. The stock is currently trading 3.82% above its 20-day simple moving average (SMA20), while that difference is up 3.16% for SMA50 and it goes to -10.21% lower than SMA200.
GSK Plc ADR (NYSE: GSK) currently have 2.04B outstanding shares and institutions hold larger chunk of about 15.23% of that.
The stock has a current market capitalization of $71.53B and its 3Y-monthly beta is at 0.64. PE ratio of stock for trailing 12 months is 22.81, while it has posted earnings per share of $1.54 in the same period. Its PEG reads 4.88 and has Quick Ratio of 0.53 while making debt-to-equity ratio of 1.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GSK, volatility over the week remained 1.43% while standing at 1.38% over the month.
Stock’s fiscal year EPS is expected to drop by -2.66% while it is estimated to increase by 4.77% in next year. EPS is likely to grow at an annualized rate of 4.67% for next 5-years, compared to annual growth of 4.23% made by the stock over the past 5-years.
Coverage by Jefferies stated GSK Plc ADR (GSK) stock as a Hold in their note to investors on November 12, 2024, suggesting a price target of $39.50 for the stock. Stock get a Neutral rating from Goldman on May 30, 2024.
